Simvastatin effectively reduced all triglyceride-rich liporoteins (VLDL and LDL) in type 2 diabetes using VAP analysis.
D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000097:blood / Q000187:drug effects; D053419:Lipoproteins, IDL / Q000097:blood / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects*; D008079:Lipoproteins, VLDL / Q000097:blood / Q000187:drug effects*; D010316:Particle Size; D019821:Simvastatin / Q000494:pharmacology* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D053419:Lipoproteins, IDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D019821:Simvastatin